Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NAMS NYSE:OGN NASDAQ:ORKA NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAMSNewAmsterdam Pharma$38.31+9.9%$31.77$16.78▼$42.00$4.40B0.02861,904 shs1.97 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsORKAOruka Therapeutics$64.62+0.9%$51.60$8.91▼$91.00$3.24B-0.21.03 million shs246,074 shsTBPHTheravance Biopharma$16.82-1.2%$15.79$8.33▼$21.03$865.97M0.19546,051 shs54,345 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAMSNewAmsterdam Pharma+12.46%+22.02%+2.77%+1.60%+86.02%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%ORKAOruka Therapeutics-8.20%-6.34%+5.73%+93.86%+573.71%TBPHTheravance Biopharma+0.47%+1.67%+2.78%-16.89%+70.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAMSNewAmsterdam Pharma$38.31+9.9%$31.77$16.78▼$42.00$4.40B0.02861,904 shs1.97 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsORKAOruka Therapeutics$64.62+0.9%$51.60$8.91▼$91.00$3.24B-0.21.03 million shs246,074 shsTBPHTheravance Biopharma$16.82-1.2%$15.79$8.33▼$21.03$865.97M0.19546,051 shs54,345 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAMSNewAmsterdam Pharma+12.46%+22.02%+2.77%+1.60%+86.02%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%ORKAOruka Therapeutics-8.20%-6.34%+5.73%+93.86%+573.71%TBPHTheravance Biopharma+0.47%+1.67%+2.78%-16.89%+70.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0025.29% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.32% DownsideORKAOruka Therapeutics 2.82Moderate Buy$120.8086.93% UpsideTBPHTheravance Biopharma 2.75Moderate Buy$21.8329.84% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, OGN, NAMS, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.004/27/2026ORKAOruka Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$200.004/27/2026ORKAOruka Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $151.004/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNAMSNewAmsterdam Pharma$22.50M195.76N/AN/A$5.97 per share6.42OGNOrganon & Co.$6.22B0.56$5.73 per share2.32$3.44 per share3.87ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/ATBPHTheravance Biopharma$107.46M8.06N/AN/A$5.86 per share2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNAMSNewAmsterdam Pharma-$203.82M-$1.73N/AN/AN/A-906.22%-26.67%-24.82%N/AOGNOrganon & Co.$187M$0.9314.313.871.243.99%99.95%6.22%N/AORKAOruka Therapeutics-$105.43M-$1.86N/AN/AN/AN/A-25.48%-24.34%5/13/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.038.2867.26N/A98.54%16.76%9.23%5/14/2026 (Estimated)Latest TBPH, OGN, NAMS, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 million5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52N/AN/AN/AN/AN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.48-$0.40+$0.08-$0.40$2.14 million$3.04 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 million2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ALatest TBPH, OGN, NAMS, and ORKA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNAMSNewAmsterdam PharmaN/A7.887.88OGNOrganon & Co.9.471.971.23ORKAOruka TherapeuticsN/A22.3722.37TBPHTheravance BiopharmaN/A10.9310.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNAMSNewAmsterdam Pharma89.89%OGNOrganon & Co.77.43%ORKAOruka Therapeutics56.44%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipNAMSNewAmsterdam Pharma20.84%OGNOrganon & Co.1.62%ORKAOruka Therapeutics23.49%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNAMSNewAmsterdam Pharma4114.97 million91.01 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableORKAOruka TherapeuticsN/A50.20 million38.41 millionN/ATBPHTheravance Biopharma11051.52 million47.96 millionOptionableTBPH, OGN, NAMS, and ORKA HeadlinesRecent News About These CompaniesHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockMay 7 at 10:50 AM | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHMay 7 at 10:00 AM | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7 at 8:30 AM | prnewswire.comTheravance Biopharma (TBPH) Projected to Post Earnings on ThursdayMay 7 at 4:05 AM | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street ZenMay 2, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 28, 2026 | globenewswire.comLaughing Water Capital’s New Position: Theravance Biopharma, Inc. (TBPH)April 25, 2026 | insidermonkey.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 25, 2026 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What HappenedApril 23, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance ...April 21, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 21, 2026 | globenewswire.comB. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14April 20, 2026 | insidermonkey.com8 Most Undervalued Biotech Stocks to Buy Right NowApril 18, 2026 | insidermonkey.comTheravance Stock Declines Around 17% in Three Months: Here's WhyApril 16, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 16, 2026 | prnewswire.comHere's Why Theravance Biopharma (TBPH) is a Strong Momentum StockApril 15, 2026 | zacks.comTBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP InvestigatesApril 15, 2026 | prnewswire.comTudor Investment Corp ET AL Sells 145,515 Shares of Theravance Biopharma, Inc. $TBPHApril 15, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPHApril 14, 2026 | globenewswire.comZacks Research Has Positive Estimate for TBPH Q1 EarningsApril 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBPH, OGN, NAMS, and ORKA Company DescriptionsNewAmsterdam Pharma NASDAQ:NAMS$38.31 +3.46 (+9.93%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Organon & Co. NYSE:OGN$13.30 -0.02 (-0.11%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Oruka Therapeutics NASDAQ:ORKA$64.62 +0.55 (+0.86%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Theravance Biopharma NASDAQ:TBPH$16.82 -0.21 (-1.20%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
